

# HEDIS<sup>®1</sup>: Comprehensive Diabetes Care (CDC)

## Description of the measure

Patients 18-75 years old with Diabetes (Type 1 and Type 2) who had all of the following screenings in the table below completed

## Tips for best practice

- Review diabetes services needed at each visit and follow up with patients to monitor changes
- Create standing lab orders for patients who need testing on a repeated basis
- Refer diabetic patients who are poorly controlled to an endocrinologist or to Magellan’s diabetes disease management program

Measure	Requirement (during measurement year)	Coding
HbA1c control	Most recent HbA1c is <8.0	<ul style="list-style-type: none"> <li>• 3044F (&lt;7.0)</li> <li>• 3051F (<math>\geq 7.0</math> and &lt;8.0)</li> </ul>
HbA1c poor control	Most recent HbA1c is >9.0	<ul style="list-style-type: none"> <li>• 3046F (&gt;9.0)</li> </ul>
Blood pressure control	Most recent blood pressure during the measurement year is <140/90 mm Hg	One systolic code + one diastolic code: <ul style="list-style-type: none"> <li>• 3074F (systolic &lt;130)</li> <li>• 3075F (systolic 130-139)</li> <li>• 3078F (diastolic &lt;80)</li> <li>• 3079F (diastolic 80-89)</li> </ul>
Nephropathy monitoring	<ul style="list-style-type: none"> <li>• Urine microalbumin test, or</li> <li>• Positive microalbumin test, or</li> <li>• Medical attention for nephropathy</li> </ul>	<ul style="list-style-type: none"> <li>• 3066F (treatment for nephropathy), or</li> <li>• 4010F (ACEIARB therapy)</li> </ul>

1—<sup>1</sup> HEDIS<sup>®</sup> is a registered trademark of the National Committee for Quality Assurance (NCQA)  
SWH-ALL-16285-20

	(i.e. ACEI/ARB therapy, diagnosis of nephropathy/CKD)	
Retinal eye exam	<ul style="list-style-type: none"> <li>• Retinal eye exam in the measurement year or</li> <li>• No evidence of retinopathy in the year prior</li> </ul>	<ul style="list-style-type: none"> <li>• Screening: 2022F, 2023F, 2024F, 2025F, 2026F OR 2033F</li> <li>• Negative result (from year prior): 3072F</li> </ul>